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Abstract
 
Differentiation therapy for acute myeloid leukemia uses transcriptional modulators to reprogram
cancer cells. The most relevant clinical example is acute promyelocytic leukemia (APL), which
responds dramatically to either retinoic acid (RA) or arsenic trioxide (As
 
2
 
O
 
3
 
). In many myeloid
leukemia cell lines, cyclic adenosine monophosphate (cAMP) triggers growth arrest, cell death,
or differentiation, often in synergy with RA. Nevertheless, the toxicity of cAMP derivatives and
lack of suitable models has hampered trials designed to assess the in vivo relevance of theses ob-
servations. We show that, in an APL cell line, cAMP analogs blocked cell growth and unraveled
As
 
2
 
O
 
3
 
-triggered differentiation. Similarly, in RA-sensitive or RA-resistant mouse models of
APL, continuous infusions of 8-chloro-cyclic adenosine monophosphate (8-Cl-cAMP) triggered
major growth arrest, greatly enhanced both spontaneous and RA- or As
 
2
 
O
 
3
 
-induced differentia-
tion and accelerated the restoration of normal hematopoiesis. Theophylline, a well-tolerated
phosphodiesterase inhibitor which stabilizes endogenous cAMP, also impaired APL growth and
enhanced spontaneous or As
 
2
 
O
 
3
 
-triggered cell differentiation in vivo. Accordingly, in an APL
patient resistant to combined RA–As
 
2
 
O
 
3
 
 therapy, theophylline induced blast clearance and re-
stored normal hematopoiesis. Taken together, these results demonstrate that in vivo activation of
cAMP signaling contributes to APL clearance, independently of its RA-sensitivity, thus raising
hopes that other myeloid leukemias may benefit from this therapeutic approach.
Key words: theophylline • arsenic • retinoic acid • transgenic mice • clinical trial
 
Introduction
 
The different forms of acute myeloid leukemias (AMLs)
 
*
 
are characterized by the arrest of cell differentiation, the in-
duction of cell proliferation, and the repression of normal
hematopoiesis. These malignancies are often associated
with recurrent chromosomal translocations, most of which
encode fusion proteins derived from transcription factors
(1). Functional analyses of several of these fusion proteins
have shown that they behave like potent transcriptional re-
pressors (2). Repression is often achieved through the
modification of chromatin structure by histone desacety-
lases which blocks the expression of unidentified genes that
control myeloid differentiation. Transcription therapy at-
tempts to induce the reexpression of these genes and thus
restore differentiation. The inhibition of desacetylases by a
variety of compounds has been fairly effective in cell cul-
ture (3) and in animal models of leukemia (4), but as yet,
there only is slight evidence of its beneficial effects in clini-
cal settings
 
 
 
(5). To date, the only real clinical success of
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
 
.
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transcription/differentiation therapy has been in acute
promyelocytic leukemia (APL), for which two drugs, ret-
inoic acid (RA) and arsenic trioxide (As
 
2
 
O
 
3
 
) induce re-
missions (6, 7). The action of these drugs is remarkable
because they both target the oncogenic promyelocytic
leukemia (PML)–retinoic acid receptor 
 

 
 
 
(
 
RARA) fusion
protein and reverse PML/RARA–mediated repression
(8). Cyclic adenosine monophosphate (cAMP) also differ-
entiates many AML cell line and strongly synergizes with
other differentiating agents (references 9 and 10; for a re-
view, see reference 11). Moreover, in APL cells, cAMP
can decrease the concentrations of RA required for differ-
entiation to almost physiological ones (12). However, a
number of acute toxic reactions have precluded or se-
verely limited trials using cAMP derivatives (13). Here,
we used an animal model of APL derived from 
 
PML/
RARA
 
 transgenic mice (14) to study the effects of cAMP
in vivo. We showed that cAMP induces major cell
growth arrest together with differentiation and synergizes
with both As
 
2
 
O
 
3
 
 and RA to clear RA-sensitive or RA-
resistant APL. In an APL patient who had become resis-
tant to RA and As
 
2
 
O
 
3
 
 therapy, addition of theophylline,
an inhibitor of cAMP intracellular degradation, induced a
clinical remission. That activation of cAMP signaling is
beneficial in APL, independently of its sensitivity to RA,
raises hopes for the successful treatment of therapy-resistant
forms of AML.
 
Materials and Methods
 
Morphology and differentiation of the APL cell line NB4 were
evaluated on May-Grünwald Giemsa–stained cytospins. Differen-
tiation was quantified by reduction of nitroblue-tetrazolium (NBT).
8-chloro-adenosine 3-5
 
 
 
cyclic monophosphate (8-Cl-cAMP) and
8-(4-chlorophenylthio)adenosine 3-5
 
 
 
cyclic monophosphate (8-
CPT-cAMP; reference 15) were respectively obtained from the
Biology Life Research Institute and Sigma-Aldrich. 8-CPT-cAMP
was used at a concentration of 2.10
 

 
4 
 
M.
Spleen-derived leukemic blasts (10
 
7
 
) were serially passaged in syn-
geneic FVB/n mice 6 wk old, weighing 20 g, as described previously
(14). Both RA-sensitive leukemias (strain 935) or RA-resistant leu-
kemias (strain 4048; reference 16) were used. Mice were treated
according to institutional guidelines. All experiments involving mice
were repeated between two and eight times, usually with two mice in
each treatment arm. 0.5 
 

 
l/h alzet pumps were loaded with 20 mg/
ml 8-Cl-cAMP and implanted subcutaneously on the back of treated
mice. Aminophylline, a stabilized precursor of theophylline, was in-
jected intraperitoneally (100 
 

 
l/day of a 25 mg/ml solution). RA
and As
 
2
 
O
 
3
 
 treatments, autopsies, and cell or tissue analyses were
performed as described previously (14). For Western blot analysis,
a p21 mAb (BD PharMingen) was used at a 1:500 dilution.
Plasma 8-Cl-cAMP was measured by HPLC using a C18 column
(Chromosep Inertil 5 ODS3) with a 15% methanol/50 mM
phosphate buffer, pH 5.85, as a mobile phase and UV detection at
254 nm.
 
 
 
The patient studied gave informed consent to the use of
theophylline to enhance RA/As
 
2
 
O
 
3
 
 differentiation.
 
 
 
The patient’s
daily treatment consisted of 45 mg/m
 
2
 
 RA per os, 10 mg As
 
2
 
O
 
3
 
intravenously, and 250 mg theophylline per os.
Figure 1. 8-Cl-cAMP induces growth
arrest in RA-sensitive (RAS, a) or RA-resis-
tant (RAR, b) APL in mice. (Top) Spleen
weight after 7 d of 8-Cl-cAMP treatment or
no therapy (). (Middle) Bone marrow
sample after May-Grünwald Giemsa stain-
ing. Note an apoptotic cell (arrow) in the
treated sample. (Bottom) Liver from the
same mice.
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Results
 
cAMP Synergizes with As
 
2
 
O
 
3
 
 to Promote APL Cell Differen-
tiation.
 
It is well known that cAMP greatly enhances the
RA-induced differentiation of many cell lines derived from
embryonal carcinoma or myeloid leukemias, including
APL (10). As low concentrations of As
 
2
 
O
 
3
 
 were found to
induce only incomplete differentiation in an APL cell line
(7), we tested the hypothesis that cAMP would also en-
hance As
 
2
 
O
 
3
 
-induced differentiation. Even very low doses
of As
 
2
 
O
 
3 
 
combined with 8-CPT-cAMP (a low toxicity
cAMP analog) induced NBT reduction in 40% of the NB4
cells, whereas cAMP or As
 
2
 
O
 
3
 
 alone did not have signifi-
cant effects (unpublished data, see Fig. 2 a). However, high
As
 
2
 
O
 
3
 
 concentrations inhibited NBT reduction. Similarly,
only combined As
 
2
 
O
 
3
 
 and 8-CPT-cAMP induced mor-
phologic differentiation of NB4 cells into myelocyte-like
cells (unpublished data), as reported recently (17).
 
Antileukemic Effects of cAMP in Two Mouse Models of
APL.
 
To assess the possible in vivo efficiency of cAMP,
we used transplantation APL model (14) derived from
RA-sensitive 
 
PML/RARA
 
 transgenic mice (18). We de-
veloped a similar transplantation model for RA-resistant
APL, using leukemic cells from 
 
PML/RARA 
 
transgenic
mice in which a point mutation in the transgene impairs
the binding of RA to PML/RARA (16). In vivo growth
of this leukemia is much slower than in the RA-sensitive
model, liver, or spleen invasion is not as pronounced and
Figure 2. Arsenic and cAMP syn-
ergize to induce tumor regression
and differentiation in RA-sensitive
APL. (a) 8-CPT-cAMP potentiates
As2O3-induced NBT reduction at 4 d
in the APL cell line NB4. (b) In a
mouse model of APL, continuous
infusion of 8-Cl-cAMP for 3 d
greatly reduces spleen weight and
synergizes with As2O3 (As) to induce
tumor reduction (one representative
experiment). (c) CD11b expression
on bone marrow cells after 24 h of
in vivo treatments, as indicated. (d)
8-Cl-cAMP induces p21 expression
in leukemic bone marrow after 24 h
of in vivo treatment. *Cross-reactive
protein. (e and f) 8-Cl-cAMP syner-
gizes with As2O3 to eradicate leuke-
mia. 3 d of combined treatment re-
stores normal hematopoiesis in the
bone marrow (e) and induces tumor
clearance from the liver (f). (g)
Theophylline (T) therapy (3 d) in-
duces blast differentiation. Note the
synergistic action of As.
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either RA or As
 
2
 
O
 
3
 
 have mild antiproliferative effects in the ab-
sence of significant differentiation (see Fig. 4). Mice bearing es-
tablished leukemias were treated with 8-Cl-cAMP, As
 
2
 
O
 
3
 
, RA,
or combinations of these drugs and killed 1–7 d after treatment.
Continuous 8-Cl-cAMP infusions allowed significant plasma
concentrations to be reached (1
 
 
 

 
M on an average at day 3).
Despite its toxicity, 8-Cl-cAMP induced major antileukemic
effects in both RA-sensitive and RA-resistant APLs, as assessed
by spleen weight (Fig. 1) and liver or bone marrow infiltration
(Fig. 1). Myeloid cells undergoing differentiation were always
observed in the marrow of RA-resistant APL after 7 d of treat-
ment, and were often found upon treatment of RA-sensitive
APL (Fig. 1). In leukemic cells infiltrating the liver, a sharp re-
duction in the number of mitoses was observed after 8-Cl-
cAMP treatment (3% post- versus 28% pretreatment) and a few
condensed nuclei were seen (unpublished data). Apoptosis was
also noted in the bone marrow (arrow in Fig. 1 b). Taken to-
gether, these results show that in these RA-sensitive or RA-
resistant mouse models of APL, cAMP triggers a combination
of cell growth arrest, differentiation, and apoptosis, leading to
dramatic regressions of the leukemia. Nevertheless, in most
cases, cAMP was unable to eradicate APL.
Since cAMP greatly increased As
 
2
 
O
 
3
 
-triggered differentia-
tion ex vivo in the NB4 cell line (Fig. 2 a), we combined 8-Cl-
cAMP and As
 
2
 
O
 
3
 
 treatments in vivo. With this combination,
the spleen, liver, and bone marrow of mice with RA-sensitive
APL became free of leukemia between days 1 and 3, whereas
mice treated with As
 
2
 
O
 
3
 
 or cAMP alone retained a significant
tumor burden consisting of differentiating leukemic cells (Fig.
2, b, e, and f). Note that erythroblasts and megakaryocytes
were extremely numerous in a cell-rich marrow (Fig. 2 e), in
agreement with the idea that cAMP promotes the regrowth of
these cells. In keeping with our ex vivo results, cAMP syner-
gized with As
 
2
 
O
 
3
 
 to trigger differentiation, as shown by
CD11b expression on bone marrow blasts at day 1 (Fig. 2 c),
strongly suggesting that enhanced differentiation of the leuke-
mic blasts contributes to these accelerated remissions. The level
of the cdk inhibitor p21, a known cAMP target implicated in
growth arrest, differentiation, and apoptosis, rose strikingly in
bone marrow APL blasts upon treatment in vivo (Fig. 2 d).
Synergy was also noted between 8-Cl-cAMP and RA with re-
spect to both spleen weight and marrow cell differentiation, al-
though this synergy was dimmed by the stronger differentiating
effect of RA (Fig. 3).
8-Cl-cAMP induced even more dramatic regressions in
RA-resistant APL, with some morphologically complete clear-
ances (Figs. 1 and 4). Unexpectedly, major enhancements of
leukemia clearance and differentiation were always observed
when RA was combined with 8-Cl-cAMP (Fig. 4). Although
As
 
2
 
O
 
3
 
 alone triggered a slight antiproliferative effect in the ab-
sence of significant differentiation, the RA/As
 
2
 
O
 
3
 
 combination
triggered minor, but reproducible, differentiation (Fig. 4 b).
Additive effects between cAMP and As
 
2
 
O
 
3
 
 were also noted
(Fig. 4), but the significance of this interaction remains unclear.
The stable cAMP derivative used here induces massive
diuresis, precluding any long-term use, and may be further
metabolized into potentially cytotoxic nucleotide analogs
(15).
 
 
 
To ensure that the antileukemic effect indeed resulted
from the activation of cAMP signaling, we used theophyl-
line, a phosphodiesterase inhibitor which stabilized pools of
endogenous intracellular cAMP. Like 8-Cl-cAMP, the-
ophylline blocked growth in RA-sensitive APL and induced
some apoptosis, accompanied by non-terminal differentia-
tion (Fig. 2 g and unpublished data). As expected, the en-
hancement of differentiation was more pronounced with
As
 
2
 
O
 
3
 
 than with RA (Fig. 2 g and unpublished data).
However, there was no obvious boost in normal hemato-
poiesis, possibly reflecting low production of endogenous
cAMP in normal cells.
 
Theophylline Induces Remission in an RA- and As-resistant
APL Patient.
 
On the basis of these promising results in
mouse APL, an RA/As
 
2
 
O
 
3
 
-resistant APL patient was offered
an experimental course of combined RA/As
 
2O3/theophylline
therapy. Previously, a month of the RA/As2O3 combination
had led to a slow decrease in bone marrow blasts, a peak of dif-
ferentiating myeloid cells in the blood (Fig. 5), but normal he-
matopoiesis was not restored and the leukemia had reappeared
5 wk later (Fig. 5, a and b). However, with combined RA/
As2O3/theophylline treatment, leukemic cells underwent dif-
ferentiation and normal erythroblasts appeared rapidly (Fig. 5, a
and c). The patient no longer required red cell or platelet trans-
fusions and white blood cells and hemoglobin reached levels
close to the normal ones. The patient remained leukemia free
for 4 mo, but then the leukemic clone reappeared. Paradoxi-
cally, with ongoing RA/As2O3/theophylline therapy and de-
spite the leukemia relapse, normal hematopoiesis has been
Figure 3. RA and cAMP synergize to induce tumor regression and
differentiation. (a) Spleen weight after 7 d of treatment or untreated ().
(b) Corresponding bone marrow morphology.
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maintained to date (5 mo since relapse), an extremely unusual
situation in APL, in which cytopenia is the first sign of relapse.
Discussion
Our data demonstrate that in vivo activation of cAMP
signaling was beneficial in two distinct mouse models of
APL, as well as in an RA/As2O3-resistant APL patient. The
relative balance between growth arrest, apoptosis, and dif-
ferentiation presumably depends on the dose of 8-Cl-
cAMP, the microenvironment of the APL blasts (marrow
versus liver metastasis, for example) and their nature (RA-
sensitive or RA-resistant cells). cAMP-triggered growth ar-
rest may result from induction of the cdk inhibitor p21,
which was previously found to be involved in RA-induced
APL cell differentiation (19). Enhancement of RA-,
As2O3-, or rexinoid-triggered differentiation by cAMP
may also result from induction of G-CSF expression (20).
In F9 embryonal carcinoma cells, cAMP was shown to
modulate RA-triggered differentiation directly through
RARA phosphorylation (21). Since RARA plays a critical
role in myeloid differentiation, including in its regulation
by IL-3 and GM-CSF (22), the cAMP triggered myeloid
differentiation may similarly be caused by modulation of
RARA signaling. At present, we cannot explain the greater
sensitivity to 8-Cl-cAMP of RA-resistant APL cells, but it
might be due to their slower growth rate. In European tri-
als, therapy-resistant patients only exceptionally exhibit
mutations in PML/RARA, which does not favor a direct
parallel between the case of this patient and RA-resistant
APL mice. The RA/8-Cl-cAMP synergy for differentia-
tion in RA-resistant APL was unexpected. Indeed, a cell
line (NB4-LR2) that harbors a mutation in PML/RARA
very similar to the one present in the RA-resistant APL
cells used here, failed to differentiate upon combined RA/
8-Cl-cAMP treatment, but only matured upon combined
cAMP/rexinoid exposure (20). Therefore, our observa-
tions might reflect an in vivo metabolism of RA to rexi-
noids and activation of this parallel pathway. Absence of
major synergy between cAMP and As2O3 in RA-resistant
APL, compared to RA-sensitive disease, may reflect the
low potency of As2O3 and the striking efficacy of 8-Cl-
cAMP in this setting. As2O3 was initially believed to trigger
apoptosis, but recent observations have suggested that dif-
ferentiation was the dominant mechanism (for a review, see
reference 23). The dramatic enhancement of As2O3-trig-
gered differentiation by 8-Cl-cAMP both ex vivo and in
vivo (Fig. 2 and reference 17), greatly strengthens this idea.
In the patient, as in the APL mice, cAMP induced rapid re-
growth of normal erythroblasts and megakaryocytes. This
might have resulted from a direct positive effect on the
normal progenitors, as reported ex vivo (24). Alternatively,
APL cells might secrete inhibitors of normal hematopoiesis
(25, 26) whose synthesis or downstream signaling, may be
blocked by cAMP. In the clinical setting, such an in vivo
stimulatory effect on normal hematopoiesis could be as im-
portant as leukemia inhibition.
Figure 4. cAMP synergizes with RA in
RA-resistant APL. (a) Spleen weight after 7 d
of treatment. (b) Corresponding bone mar-
row morphology. Two examples of mar-
rows from mice exposed to RA and cAMP
are shown.
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The low toxicity of theophylline, its ability to accelerate
RA- or As2O3–triggered remissions and the observation
that the rapid induction of ex vivo differentiation is pre-
dictive of outcome in APL (27), could favor the use of
theophylline for de novo APL patients. cAMP is active
both in RA-sensitive and RA-resistant APL. In addition,
unlike RA and As2O3, cAMP does not obviously target
PML/RARA and might therefore be beneficial in malig-
nancies other that APL. Indeed, patients with chronic
lymphocytic leukemia experienced faster clinical remis-
sions when theophylline was combined with low-dose
chemotherapy (28). Similarly, a patient on Viagra, an-
other phosphodiesterase inhibitor, exhibited regression of
B cell chronic lymphocytic leukemia (29). Many AML-
derived cell lines are very sensitive to cAMP-triggered dif-
ferentiation, particularly in the presence of other differen-
tiation inducers. Like histone desacetylase inhibitors,
which unravel RA-induced differentiation (3, 30), the-
ophylline may greatly increase the potency of RA and
other differentiation inducers in AML patients.
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Figure 5. Theophylline synergizes with RA/
As2O3 therapy in a multirelapsed patient with RA/
As2O3-resistant APL. (a) Schematic representation
of clinical events. (b and c) Representative images of
bone marrow samples taken at days 0, 14, and 28 of
the initial RA/As2O3 course (b) or the following
RA/As2O3/theophylline course (c). Note the rapid
differentiation in (c) with the reappearance of nor-
mal erythroblasts at day 14, as well as the mainte-
nance of normal hematopoiesis despite leukemia
relapse. Hb, hemoglobin; Plt, platelet; WBC, white
blood cell.
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